Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07564414 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,500
- Enrollment target
NCT07564414 is a Phase 3 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 2,500 participants.
The verdict
NCT07564414, a Phase 3 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Interventions
- DRUG Semaglutide
- DRUG Cagrisema
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2028-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07564414
The ClinicalTrials.gov registry entry for NCT07564414 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT07564414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07564414 about?
NCT07564414 is a clinical study titled "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight". This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith...
What is the current status of trial NCT07564414?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,500 participants. The study started on 2026-05-21. Estimated completion is 2028-04-19.
What interventions are being tested in trial NCT07564414?
The interventions under investigation include: Semaglutide (DRUG), Cagrisema (DRUG).
Who is sponsoring clinical trial NCT07564414?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.